Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi E Komatsu

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2019
Hepatitis C Virus RNA Levels Following Virologic Failure With Direct-acting Antivirals: Implications for Lower Sensitivity Diagnostic AssaysPatrick R Harrington, Takashi E Komatsu, Hengrui Sun, et al.
Antiviral Research|November 5, 2013
Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathwaysTakashi E Komatsu, Andreas Pikis, Lisa K Naeger, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 25, 2020
No Association Between DAA Treatment for HCV Infection and Herpes Zoster Infection in Analysis of Data From 37 Clinical TrialsMaximilian D Rohde, LaRee Tracy, Takashi E Komatsu, et al.
Clinical Drug Investigation|January 20, 2017
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 InfectionSarita D Boyd, LaRee Tracy, Takashi E Komatsu, et al.
Gastroenterology|October 25, 2016
Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and GrazoprevirTakashi E Komatsu, Sarita Boyd, Adam Sherwat, et al.
Hepatology (Baltimore, Md.)|December 2, 2017
Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectivesPatrick R Harrington, Takashi E Komatsu, Damon J Deming, et al.
Virology Journal|December 1, 2019
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodiesNatalia A Ilyushina, Takashi E Komatsu, William L Ince, et al.
Journal of Clinical Pharmacology|December 27, 2018
Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future PerspectivesAimee C Hodowanec, Andreas Pikis, Takashi E Komatsu, et al.
Antiviral Research|July 8, 2019
In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene productsTakashi E Komatsu, Aimee C Hodowanec, Anamaris M Colberg-Poley, et al.
Scientific Reports|July 8, 2021
Informing selection of drugs for COVID-19 treatment through adverse events analysisWenjing Guo, Bohu Pan, Sugunadevi Sakkiah, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2019
Hepatitis C Virus RNA Levels Following Virologic Failure With Direct-acting Antivirals: Implications for Lower Sensitivity Diagnostic AssaysPatrick R Harrington, Takashi E Komatsu, Hengrui Sun, et al.
Antiviral Research|November 5, 2013
Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathwaysTakashi E Komatsu, Andreas Pikis, Lisa K Naeger, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 25, 2020
No Association Between DAA Treatment for HCV Infection and Herpes Zoster Infection in Analysis of Data From 37 Clinical TrialsMaximilian D Rohde, LaRee Tracy, Takashi E Komatsu, et al.
Clinical Drug Investigation|January 20, 2017
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 InfectionSarita D Boyd, LaRee Tracy, Takashi E Komatsu, et al.
Gastroenterology|October 25, 2016
Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and GrazoprevirTakashi E Komatsu, Sarita Boyd, Adam Sherwat, et al.
Hepatology (Baltimore, Md.)|December 2, 2017
Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectivesPatrick R Harrington, Takashi E Komatsu, Damon J Deming, et al.
Virology Journal|December 1, 2019
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodiesNatalia A Ilyushina, Takashi E Komatsu, William L Ince, et al.
Journal of Clinical Pharmacology|December 27, 2018
Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future PerspectivesAimee C Hodowanec, Andreas Pikis, Takashi E Komatsu, et al.
Antiviral Research|July 8, 2019
In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene productsTakashi E Komatsu, Aimee C Hodowanec, Anamaris M Colberg-Poley, et al.
Scientific Reports|July 8, 2021
Informing selection of drugs for COVID-19 treatment through adverse events analysisWenjing Guo, Bohu Pan, Sugunadevi Sakkiah, et al.
Pageof 2